ECU
MDGL icon

Eisler Capital (US)’s Madrigal Pharmaceuticals MDGL Stock Holding History

Eisler Capital (US)’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-2,885
Closed -$808K – 593
2024
Q2 		$808K Buy
+2,885
New +$687K 0.01% 518

Other funds holding MDGL

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Eisler Capital (US)'s MDGL Position: Q3 2024 in Review

Eisler Capital (US) sold out of Madrigal Pharmaceuticals (MDGL) in Q3 2024, closing a stake of 2,885 shares — an estimated $808K sold.

Eisler Capital (US) first reported a position in MDGL in Q2 2024 and held it in 1 quarter. The position peaked at $808K in Q2 2024. 257 funds tracked by Wall St. Rank hold MDGL as of Q3 2024.

  • Eisler Capital (US) reported no remaining Madrigal Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • Eisler Capital (US) sold 2,885 Madrigal Pharmaceuticals shares in Q3 2024, an estimated $808K.
  • Eisler Capital (US) first reported a position in Madrigal Pharmaceuticals in Q2 2024 and held it in 1 quarter.
  • Eisler Capital (US)'s Madrigal Pharmaceuticals position peaked at $808K in Q2 2024.
  • 257 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q3 2024.

Based on Eisler Capital (US)'s 13F filing for Q3 2024, filed 14 Nov 2024.